Shares of Utah Medical Products, Inc. UTMD have declined 4.6% since the company reported its earnings for the quarter ended Dec. 31, 2024. This compares to the S&P 500 index’s 0.5% growth over the same time frame. Over the past month, the stock has declined 0.4% compared with the S&P 500’s 2.8% growth.
See the Zacks Earnings Calendar to stay ahead of market-making news.
For the fourth quarter of 2024, Utah Medical reported earnings per share (EPS) of 86 cents, representing a 27.4% decrease from $1.18 in the fourth quarter of 2023.
Total revenues of $9.2 million reflected a 25.8% decline from $12.3 million in the year-ago quarter. The decrease was driven by weaker sales across key product categories, including a significant drop in revenues from PendoTECH OEM sales and lower sales to outside-the-U.S. (OUS) distributors.
Net income for the quarter was $2.9 million, down 32.3% from $4.3 million in the same period last year.
For the full year, Utah Medical reported revenues of $40.9 million, an 18.6% decline from $50.2 million in 2023. Net income for 2024 fell 16.6% to $13.9 million from $16.6 million, while EPS dropped 13.4% to $3.96 from $4.57.
Utah Medical Products, Inc. Price, Consensus and EPS Surprise
Utah Medical Products, Inc. price-consensus-eps-surprise-chart | Utah Medical Products, Inc. Quote
Key Business Metrics for UTMD
Despite the decline in revenues, Utah Medical maintained relatively stable gross profit margins. The fourth-quarter gross margin was 58.1%, slightly higher than 57.6% the prior-year period. Full-year gross margin stood at 59%, down slightly from 59.8% in 2023.
Operating income for the fourth quarter declined 25.7% year over year to $2.9 million, while full-year operating income fell 19% to $13.6 million.
Cash and investments totaled $83 million as of Dec. 31, 2024, down from $92.9 million a year earlier.
Management Commentary for UTMD
The company attributed the revenue decline to three primary factors: a $5.9 million drop in PendoTECH sales, lower OUS distributor sales, and a 12% decline in worldwide Filshie Clip System device sales.
Despite additional cost-of-living adjustments for employees and ongoing inflation in raw material costs, Utah Medical managed to sustain its profit margins through efficiency measures, including workforce reductions and the closure of a second production shift in Utah.
Factors Influencing UTMD’s Results
A significant contributor to the revenue decline was a sharp reduction in orders from PendoTECH, which accounted for 64% of the total revenue drop. The company also experienced a $2.1 million decrease in OUS distributor sales, primarily due to reduced shipments of blood pressure monitoring kits to China. Filshie Clip System sales were down 12%, with declines across both domestic and OUS markets.
Companies ride the wave of AI for enhanced efficiency and superior quality, a groundbreaking ISG Provider Lens™ report highlights
Amidst the rapid evolution of artificial intelligence and cloud technologies, U.S. enterprises have undergone a metamorphosis in their approach to application development and management (ADM) strategies as per the latest research published by Information Services Group (ISG) III, a prominent global technology research and advisory firm.
Entrenched in a quest for cost optimization, U.S. companies have embraced AI technologies throughout the lifecycles of applications, catapulting the adoption of generative AI (GenAI) in early developmental stages, asserts the 2024 ISG Provider Lens™ Next-Gen ADM Services report for the U.S.
Leveraging AI tools has led to the automation of ADM tasks, resulting in enhanced software quality, minimized downtime, and boosted efficiency, as outlined in the report. This automation journey contributes to heightened developer productivity, reduced time to market, and proactive maintenance practices.
Prioritizing quality assurance, U.S. enterprises are exploring GenAI's potential applications in this realm. By automating test creation and scenario simulation, GenAI accelerates testing processes, uncovering discrepancies that might elude manual inspections. Companies tread cautiously, endeavoring to embed quality assurance mechanisms in GenAI to ensure ethical and optimal functionality.
A notable trend sees an increasing number of U.S. enterprises consolidating applications and underlying IT infrastructure engagements, enwrapping servers, networks, and cloud services, heralding optimized performance, scalability, security, and cost-efficiency, discloses the report.
Enterprises are gravitating towards major public cloud platforms for robust, scalable, and flexible applications, facilitated by orchestration tools like Kubernetes, microservices architectures, containerization, and DevOps methodologies. This strategic shift to the cloud harmonizes with market dynamics, enabling enterprises to pivot swiftly in response to evolving customer needs.
Fusion of site reliability engineering (SRE) with AI for IT operations (AIOps) heralds a new epoch in ADM operations, affirms the report. This blend harnesses machine learning and advanced analytics to navigate vast operational datasets, empowering companies with holistic insights into system performance and the ability to preemptively address potential glitches for seamless service delivery.
The report delves into additional ADM trends in the U.S., spotlighting providers' adeptness in catering to industry-specific demands, and the ascendancy of Agile and DevOps practices in continuous testing services, underpinning a narrative of ongoing evolution and adaptability in the technology sphere.
In addition, Utah Medical faced higher litigation expenses, increased salary costs and the impact of a newly introduced excise tax on share repurchases. Non-operating income was lower year over year, primarily due to the absence of rental income in Ireland, which had contributed significantly in 2023.
UTMD’s Guidance
Management expects total worldwide revenues to decline again in 2025, though at a lower rate than in 2024. While PendoTECH sales are projected to decline further, the company anticipates a slight rebound in OUS distributor sales and Filshie device revenues.
Other Developments for UTMD
During 2024, Utah Medical repurchased more than 301,000 shares at an average price of $66.13 per share, totaling nearly $20 million. The company also increased its quarterly dividend to 30.5 cents per share, effective January 2025.
Research Chief Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Utah Medical Products, Inc. (UTMD): Free Stock Analysis Report
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.